NCT02779855 2026-03-10
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
Clinical Trials
22 trialsNCT04599062 2026-01-29
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
University of Iowa
Phase 1/2 Active not recruiting
NCT02965716 2025-11-18
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03069378 2025-10-29
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04068181 2025-01-07
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Amgen
Phase 2 Completed
NCT03663712 2024-11-20
TEMPO
Duke University
Phase 1 Completed
NCT02509507 2024-08-06
MASTERKEY-318
Amgen
Phase 1/2 Completed
NCT02453191 2024-06-20
TVEC and Preop Radiation for Sarcoma (4 ml Dose)
University of Iowa
Phase 1/2 Completed
NCT03300544 2024-05-23
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03256344 2024-05-14
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Amgen
Phase 1 Completed
NCT02756845 2024-02-20
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Amgen
Phase 1 Completed
NCT02658812 2023-01-25
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT02366195 2021-11-30
TVEC-325
Amgen
Phase 2 Completed
NCT02626000 2021-09-08
MASTERKEY232
Amgen
Phase 1 Completed
NCT03597009 2021-04-20
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02014441 2019-11-20
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Amgen
Phase 2 Completed
NCT00402025 2016-04-15
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
BioVex Limited
Phase 1 Completed
NCT01161498 2016-02-08
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
BioVex Limited
Phase 3 Terminated
NCT00289016 2015-12-18
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
BioVex Limited
Phase 2 Completed
NCT02574260 2015-12-17
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
BioVex Limited
Phase 2 Completed